Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | 0.17% | 358.71 | 1.2% | $830.53m | |
| AMGN | Amgen Inc. | -0.66% | 190.49 | 1.2% | $543.11m | |
| CELG | Celgene Corporation | -0.28% | 85.10 | 1.2% | $507.54m | |
| GILD | Gilead Sciences, Inc. | 0.42% | 77.37 | 0.9% | $473.45m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.51% | 177.40 | 1.9% | $313.54m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.17% | 367.11 | 2.6% | $276.88m | |
| ILMN | Illumina, Inc. | 0.66% | 311.15 | 3.5% | $269.38m | |
| BLUE | Bluebird Bio, Inc. | 0.78% | 180.35 | 15.7% | $197.52m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.64% | 133.31 | 16.6% | $196.81m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.05% | 135.16 | 2.0% | $178.57m | |
| NKTR | Nektar Therapeutics | -0.71% | 48.73 | 5.6% | $172.03m | |
| EXAS | Exact Sciences Corporation | 0.02% | 67.62 | 25.4% | $155.70m | |
| EXEL | Exelixis, Inc. | -0.23% | 21.29 | 6.4% | $135.36m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.94% | 101.90 | 4.4% | $122.64m | |
| A | Agilent Technologies, Inc. | -0.45% | 63.86 | 1.5% | $110.57m |
Company Profile
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.